Regulation of immunomodulatory networks by Nrf2-activation in immune cells: Redox control and therapeutic potential in inflammatory diseases

Pant, Tarun; Uche, Nnamdi; Juric, Matea; Zielonka, Jacek; Bai, Xiaowen

doi:10.1016/j.redox.2024.103077

Cited by 17 publications

(2 citation statements)

References 234 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Redox signaling pathways in immune cells are complex mechanisms. The expression and signaling of NRF2 may control the activity of redox-sensitive immunoregulatory molecules that affect immune cell subsets' functional status [20]. NRF2 is an important regulator of anti-inflammatory gene expression, and its effect on immune responses can vary depending on the context.…”

Section: Nfr2 Involved In Hallmarks Of Cancermentioning

confidence: 99%

The Dual Role of NRF2 Transcription Factor in Female Cancer

Bruneska Gondim Martins,

Cristina de Aguiar,

Maria de Araújo Barbosa

et al. 2024

The Role of NRF2 Transcription Factor [Working Title]

View full text Add to dashboard Cite

Nuclear factor erythroid 2-related factor 2 (NRF2) is an essential transcription factor that is involved in cellular defense against oxidative stress and is assumed to be an important molecule in the transcription and regulation of cytoprotective genes. NRF2 is not only responsible for protecting healthy cells but plays a role in neoplastic cells once high expression of NRF2 has been observed in cancer cells. However, the increase in NRF2 levels may be correlated with resistance to therapy, making it interesting to understand the duality of the protective action of this molecule in the scenario of the cancer hallmarks, NRF2-regulated target genes involved in redox homeostasis, drug metabolism and excretion, amino acid metabolism, iron metabolism, energetic metabolism, survival, autophagy, proliferation, DNA repair, proteasomal degradation, and mitochondrial physiology. Therefore, NRF2 has emerged as a promising target in cancer treatment, and many efforts have been made to identify therapeutic strategies that inhibit its oncogenic role.

show abstract

Section: Nfr2 Involved In Hallmarks Of Cancermentioning

confidence: 99%

The Dual Role of NRF2 Transcription Factor in Female Cancer

Bruneska Gondim Martins,

Cristina de Aguiar,

Maria de Araújo Barbosa

et al. 2024

The Role of NRF2 Transcription Factor [Working Title]

View full text Add to dashboard Cite

show abstract

“…Various immune cell subsets, including macrophages, dendritic cells, T cells, and natural killer cells, have been shown to express Nrf2 and exhibit altered phenotypes upon its modulation. This modulation extends beyond traditional antioxidant and detoxification pathways, implicating Nrf2 in the regulation of immune cell development, activation, differentiation, and effector functions [9].…”

Section: Introductionmentioning

confidence: 99%

Nrf2 as a therapy target for Th17-dependent autoimmune disease

Wu,

Zhong

2024

The Role of NRF2 Transcription Factor [Working Title]

View full text Add to dashboard Cite

Th17 cells are a subset of IL-17-expressing CD4+ T helper cells and play a predominant role in the pathogenesis of autoimmune diseases such as multiple sclerosis and psoriasis. Th17 cells sustain their activation and effector functions primarily through a metabolic profile characterized by high glycolytic and oxidative metabolism. Both glycolysis and OXPHOs can affect cellular redox status, and vice versa. Nrf2, a master regulator of redox homeostasis, plays a pivotal role in oxidative stress regulation and influences immune cell function. This chapter summarizes the recent advances in the understanding of redox regulation in Th17 cells and explores the therapeutic potential of targeting Nrf2 in Th17-dependent autoimmune diseases. Overall, targeting Nrf2 holds considerable promise as a novel therapeutic paradigm for Th17-dependent autoimmune diseases, offering new avenues for precision medicine and improved disease outcomes.

show abstract

Disruption of Ferroptosis Inhibition and Immune Evasion with Tumor‐Activatable Prodrug for Boosted Photodynamic/Chemotherapy Eradication of Drug‐Resistant Tumors

Bi,

Zhao,

Wang

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Breast cancer is a malignant tumor that threatens the life and health of women worldwide. As the first‐line chemotherapy drug for breast cancer, doxorubicin (DOX) can inhibit the synthesis of RNA and DNA, and it exhibits strong inhibitory activity against breast cancer. However, drug‐induced systemic toxicity and drug resistance can occur with DOX treatment. In this work, TSPO protein is identified as a promising target for overcoming drug resistance and we designed a novel BT‐DOX/PDP conjugate to solve these problems in drug chemotherapy. It is found that BT‐DOX/PDP can effectively downregulate TSPO1 protein and sensitize MCF‐7/Adr to DOX. Furthermore, due to its positive charge, BT‐DOX/PDP is readily loaded into puerarin (PUE), the resulting BT‐DOX/PDP@PUE exhibited minimal systemic toxicity but enhanced antitumor activity in animal models, as compared with BT‐DOX/PDP. This study demonstrates the advantages of combined chemotherapy and photodynamic therapy in overcoming drug resistance, which may be applied in the design of other photodynamic therapy‐based conjugates to enhance antitumor therapy.

show abstract

Regulation of immunomodulatory networks by Nrf2-activation in immune cells: Redox control and therapeutic potential in inflammatory diseases

Cited by 17 publications

References 234 publications

The Dual Role of NRF2 Transcription Factor in Female Cancer

The Dual Role of NRF2 Transcription Factor in Female Cancer

Nrf2 as a therapy target for Th17-dependent autoimmune disease

Disruption of Ferroptosis Inhibition and Immune Evasion with Tumor‐Activatable Prodrug for Boosted Photodynamic/Chemotherapy Eradication of Drug‐Resistant Tumors

Contact Info

Product

Resources

About